Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Healthtrust
Fish and Richardson
US Department of Justice
Boehringer Ingelheim
Dow
Chinese Patent Office
Cerilliant

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203146

« Back to Dashboard

NDA 203146 describes RIZATRIPTAN BENZOATE, which is a drug marketed by Apotex Inc, Aurobindo Pharma Ltd, Glenmark Pharms Ltd, Jubilant Generics, Macleods Pharms Ltd, Mylan Pharms Inc, Natco Pharma Ltd, Panacea Biotec Ltd, Sandoz, Unichem Labs Ltd, Alkem Labs Ltd, Cipla Ltd, Eci Pharms Llc, Emcure Pharms Ltd, Glenmark Generics, Invagen Pharms, and Teva Pharms, and is included in twenty-five NDAs. It is available from twenty-four suppliers. Additional details are available on the RIZATRIPTAN BENZOATE profile page.

The generic ingredient in RIZATRIPTAN BENZOATE is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for 203146
Tradename:RIZATRIPTAN BENZOATE
Applicant:Macleods Pharms Ltd
Ingredient:rizatriptan benzoate
Patents:0
Therapeutic Class:Antimigraine Agents
Pharmacology for NDA: 203146
Suppliers and Packaging for NDA: 203146
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 203146 ANDA Macleods Pharmaceuticals Limited 33342-093 N 33342-093-12
RIZATRIPTAN BENZOATE rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 203146 ANDA Macleods Pharmaceuticals Limited 33342-093 N 33342-093-07

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 5MG BASE
Approval Date:Sep 19, 2014TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Sep 19, 2014TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Dow
Boehringer Ingelheim
McKesson
US Department of Justice
Citi
Cipla
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.